Results 11 to 20 of about 49,818 (236)

C-erbB-2 in Serum of Patients Receiving Fractionated Paclitaxel Chemotherapy

The International Journal of Biological Markers, 1999
Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC).
D. Lüftner, S. Schnabel, K. Possinger
doaj   +1 more source

C-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Clinical Stage and Prognosis

The International Journal of Biological Markers, 2001
The aim of this study was to investigate the expression of the oncogene c-erbB-2 in gastric tumors. Immunohistochemical study of the expression of c-erbB-2 was performed in formalin-fixed, paraffin-embedded sections from 82 gastric adenocarcinomas using ...
C.T.F. Oshima, V. Pereira Lanzoni, K. Iriya, N.M. Forones   +3 more
doaj   +1 more source

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy [PDF]

, 2002
Concentrations of soluble c-erbB-2 were determined in the sera of 64 patients with distant metastasis from advanced breast cancer receiving second-line hormone or chemotherapy in comparison to 35 breast cancer patients without detectable recurrent ...
Classen, S., Eiermann, W., Kopp, R., Possinger, K., Weidenhagen, R., Wilmanns, W.   +5 more
core   +1 more source

The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas

Diagnostic Pathology, 2010
Background Endometrial carcinoma (EC) is the most common malignancy of the female genital tract. Gene alterations and overexpression of various oncogenes are important in tumor development.
Kandemir Nilufer, Barisik Nagehan, Keser Sevinc, Gul Aylin, Cakır Caglar, Sensu Sibel, Karadayi Nimet   +6 more
doaj   +1 more source

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

c-erbB-2 oncoprotein expression in primary human tumors [PDF]

Cancer, 1990
Using a specific antiserum (21N) to the c-erbB-2 oncoprotein, a total of 405 primary malignant human tumors arising in the breast (n = 191), lung (n = 110), colon/rectum (n = 23), bladder (n = 48), prostate (n = 23), and skin (n = 10) were stained immunohistochemically to detect those tumors that over-expressed this putative transmembrane receptor ...
A, McCann, P A, Dervan, P A, Johnston, W J, Gullick, D N, Carney   +4 more
openaire   +2 more sources

Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies

The International Journal of Biological Markers, 1993
Selected murine monoclonal antibodies (MAb) have been shown to inhibit relevant tumor growth in vitro and in animal models. Recently, bispecific antibodies (BsMAb) have been developed which target cytolytic effector cells via one antibody binding site ...
I. Garcia De Palazzo, A. Klein-Szanto, L. M. Weiner   +2 more
doaj   +1 more source

Skor Histologi C-Erbb-2, Proliferasi Endotel Pembuluh Darah: Pada Infiltrasi Levobupivakain Terhadap Penyembuhan Luka

JAI (Jurnal Anestesiologi Indonesia), 2009
Latar Belakang: Nyeri akut paska bedah memicu timbulnya gejala klinis patofisiologis, menekan respon imun, sehingga menyebabkan penurunan sistem imun yang akan menghambat penyembuhan luka. Levobupivakain, anestetik lokal durasi panjang efektif mengurangi
Curniawati Trisasi, Marwoto Marwoto
doaj   +1 more source

Clinical-pathological features of an occult mixed mucinous male breast cancer. a case report [PDF]

, 2017
Mucinous carcinoma of the male breast is an uncommon malignant breast neoplasm and its diagnoses remain difficult. It is probably due to such a low rate of breast cancer cases that men tend to be diagnosed at an older age than women and with a later ...
Bonifacino, Adriana, Carico, Elisabetta, Giarnieri, Enrico, Giovagnoli, Maria Rosaria, Lamberti, Ilaria, Mancini, Rita, Scarpino, Stefania, Villani, Sandra   +7 more
core   +1 more source

Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models. [PDF]

, 2015
We have previously developed mouse models of HER-2-positive cervical cancer. Tumors in nude mice had histological structures similar to the original tumor and were stained by anti-HER-2 antibody in the same pattern as the patient's cancer.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Mii, Sumiyuki, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Tanaka, Kuniya, Uehara, Fuminari, Yamamoto, Mako, Yano, Shuya, Zhang, Nan, Zhang, Yong, Zhao, Ming   +19 more
core   +6 more sources